Drug Type Small molecule drug |
Synonyms Sodelglitazar (USAN), 677954, GSK 677954 + [3] |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC23H21F4NO3S2 |
InChIKeyZUGQWAYOWCBWGM-UHFFFAOYSA-N |
CAS Registry447406-78-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06647 | Sodelglitazar | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 2 | AR | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | AU | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | CL | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | CR | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | IN | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | LV | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | MX | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | NZ | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | PK | 01 Dec 2005 | |
Dyslipidemias | Phase 2 | RO | 01 Dec 2005 |